Comment
EGFR R521K predicts cetuximab response in KRAS wild-type patients
Affiliations
- PMID: 22754965
Item in Clipboard
Comment
EGFR R521K predicts cetuximab response in KRAS wild-type patients
Pharmacogenomics.
2012 May.
No abstract available
Comment on
-
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.Cancer Sci. 2012 Apr;103(4):791-6. doi: 10.1111/j.1349-7006.2012.02225.x. Epub 2012 Feb 22. Cancer Sci. 2012. PMID: 22321154 Free PMC article.
Similar articles
-
A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer.Int J Genomics. 2014;2014:312102. doi: 10.1155/2014/312102. Epub 2014 Oct 21. Int J Genomics. 2014. PMID: 25401099 Free PMC article.
-
The Relations between EGFR R521K Polymorphism and Risk of Cancer: Need for Clarification of Data in a Recent Meta-Analysis.Int J Genomics. 2015;2015:597413. doi: 10.1155/2015/597413. Epub 2015 Mar 19. Int J Genomics. 2015. PMID: 25874199 Free PMC article. No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous